Microsatellite Instability clinical trials

The registry lists 58 studies for Microsatellite Instability across more than 10 countries. 9 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-09-24.

Studies

Recruiting first, then most recently updated. Showing 50 of 58 — search for more.

• Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual DiseaseRecruitingNCT07750158Phase 31 country
• A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid TumorsRecruitingNCT06004245Phase 111 countries
• A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid TumorsRecruitingNCT05592626Phase 1/24 countries
• A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.RecruitingNCT06898450Phase 1/28 countries
• Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study.Not yet recruitingNCT06646445Phase 21 country
• Different Cycles of Preoperative Neoadjuvant Sintilimab in Mismatch-repair Deficient/microsatellite Instability-high, Locally Advanced Colorectal CancerRecruitingNCT06698757Phase 21 country
• PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsatellite Unstable or Mismatch Repair-deficient Locally Advanced Rectal Cancer PatientsRecruitingNCT06762405Phase 31 country
• Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal CancerRecruitingNCT06520683Phase 31 country
• Cadonilimab as Neoadjuvant Therapy in Resectable Stage II-III MSI-H/dMMR Colorectal CancerNot yet recruitingNCT05913570Phase 21 country
• Liquid Biopsy Biomarkers for Endoscopic Surveillance in Lynch SyndromeCompletedNCT078382461 country
• TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC.Active, not recruitingNCT04817826Phase 21 country
• Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid CancersActive, not recruitingNCT03935893Phase 21 country
• Development and Validation of the Surgical Assessment and Healthcare (SAH) Index for Gastric Cancer Treatment EvaluationCompletedNCT071809661 country
• Neoadjuvant Prolgolimab Monotherapy in Locally Advanced MMR-deficient Colorectal CancerCompletedNCT06428487Phase 21 country
• Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 InhibitorActive, not recruitingNCT03607890Phase 21 country
• Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation StatusCompletedNCT03519412Phase 21 country
• First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined CancersTerminatedNCT06625515Phase 11 country
• QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsActive, not recruitingNCT03228667Phase 21 country
• Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)Active, not recruitingNCT02628067Phase 2
• National Cohort of Colorectal Cancers With Microsatellite InstabilityActive, not recruitingNCT055116881 country
• iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and IpilimumabActive, not recruitingNCT03350126Phase 21 country
• Dynamics of MSI and Genomic Profile of Colorectal Cancer In the Course of Immune Checkpoint Inhibitor TherapyCompletedNCT064143041 country
• Frequency of Endometrial Cancer Precursors Associated with Lynch SyndromeCompletedNCT052570571 country
• Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid TumorsTerminatedNCT05909995Phase 13 countries
• A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)WithdrawnNCT06331598Phase 21 country
• M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite InstabilityCompletedNCT03436563Phase 1/21 country
• IBI310 in Combination with Sintilimab in Patients with DNA Mismatch Repair Deficient (dMMR)/microsatellite Instability High (MSI-H) Locally-advanced or Metastatic Colorectal CancerTerminatedNCT04258111Phase 21 country
• Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer TypesTerminatedNCT06034860Phase 11 country
• Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)CompletedNCT02563002Phase 3
• A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid TumorsCompletedNCT02791334Phase 17 countries
• Detection of MSI in Circulating Tumor DNA of Colorectal Carcinoma PatientsTerminatedNCT035944481 country
• Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer TypesCompletedNCT03012581Phase 21 country
• Molecular Characteristics of Early-onset Compared With Late-onset Colorectal CancerCompletedNCT06238193
• Cycling in Preventing Colorectal Cancer in Participants With Lynch SyndromeCompletedNCT03495674Not applicable1 country
• LITT and Pembrolizumab in Recurrent Brain MetastasisTerminatedNCT04187872Phase 11 country
• Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular ImmunotherapyTerminatedNCT041061671 country
• FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid TumorsCompletedNCT03841110Phase 11 country
• Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon CancerTerminatedNCT03827044Phase 31 country
• Phase Ib/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric CancerCompletedNCT05535569Phase 1/21 country
• The Relationship Between Microsatellite Instability and Efficacy of Fluorouracil Based Adjuvant Chemotherapy in Gastric Cancer After OperationCompletedNCT034851961 country
• Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal CancerStatus unknownNCT05371197Phase 21 country
• APL-501 Study for Select Advanced or Relapsed/Recurrent Solid TumorsCompletedNCT03053466Phase 11 country
• Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid TumorsActive, not recruitingNCT03836352Phase 22 countries
• Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected CancersCompletedNCT02178722Phase 1/21 country
• Microsatellite Instability in Colorectal CancersCompletedNCT051622481 country
• Anti-PD-1 +/- RT for MSI-H Solid TumorsWithdrawnNCT04001101Phase 21 country
• A Safety and Tolerability Study of INCAGN02385 in Select Advanced MalignanciesCompletedNCT03538028Phase 11 country
• A Retrospective Validations Microsatellite Instability (MSI) Testing v Mismatch Repair (MMR) in Gastric AdenocarcinomaCompletedNCT042320201 country
• The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and SurvivalCompletedNCT044826081 country
• Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)CompletedNCT01876511Phase 21 country